An IL-2 Receptor Targeted Toxin with Reduced VLS

具有减少 VLS 的 IL-2 受体靶向毒素

• 批准号: 6883320
• 负责人: JOHANNA Catharina VANDERSPEK
• 金额: $ 14.48万
• 依托单位: ANJIN GROUP, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-01 至 2006-02-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6883320
• 关键词: antineoplastics; biotechnology; chimeric proteins; cytokine receptors; diphtheria toxin; drug adverse effect; drug design /synthesis /production; drug interactions; drug screening /evaluation; enzyme activity; human tissue; immunotherapy; interleukin 2; membrane permeability; pentosyltransferase; protein engineering; protein structure function; recombinant proteins; tissue /cell culture; vascular endothelium

DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of refractory cutaneous T cell lymphoma. The fusion protein toxin technology has not been widely developed due adverse events, especially vascular leak syndrome (VLS), associated with administration of these agents. The Anjin Group Inc [AGI] proposes to develop a third generation diphtheria toxin-based platform, modified to reduce VLS. Fusion protein toxins developed from such a toxophore may have broader clinical application due to an altered risk benefit profile for patients including those with non-life threatening disease.

描述（由申请人提供）：早在十多年前，第一种基于白喉毒素的融合蛋白毒素，DAB 389 IL-2（Ontak（R））作为第一种新型受体特异性治疗剂正在开发中。这种融合蛋白在五年前获得FDA批准用于治疗难治性皮肤T细胞淋巴瘤。融合蛋白毒素技术由于与这些药剂的施用相关的不良事件，特别是血管渗漏综合征（VLS）而未被广泛开发。 Anjin Group Inc [AGI]建议开发第三代基于白喉毒素的平台，经过修改以减少VLS。从这样的毒基开发的融合蛋白毒素可能具有更广泛的临床应用，这是由于对患者（包括那些患有非危及生命的疾病的患者）的改变的风险受益概况。